Endo Investors Ask Court for First OK of $63.4 Million Deal

Oct. 18, 2021, 8:22 PM

Endo International PLC and investors who say it misled them about generic drug pricing decisions and competition asked a federal judge in Pennsylvania for initial approval of a $63.4 million deal to resolve the litigation.

The cash settlement “represents an outstanding recovery for the Class,” the pharmaceutical company’s investors said in a memo filed in support of their motion for preliminary settlement approval in the U.S. District Court for the Eastern District of Pennsylvania.

Judge Michael M. Baylson in 2020 trimmed investor claims alleging Endo made misleading statements about a price-fixing conspiracy, but he allowed allegations about competition, generics revenue, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.